United States · Platforms & data · Seeking Alpha
Insmed may be worth $170 to $210 a share in takeover, analyst

Detailed summary
RBC analyst rates Insmed Outperform: a Sanofi takeover could value shares at $170-$210, with a 20%-50% premium plausible.
Insmed (INSM) may be worth $170-$210 a share in a takeover after a report that Sanofi (SNY) is weighing a purchase of the drugmaker, according to an RBC analyst.
Opening of the article, excerpted from Seeking Alpha. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (seekingalpha.com)



